SYN321

About Synartro

Synartro is a private, clinical-stage biotech founded in 2021, leveraging a patented hyaluronan-based local injection platform to develop sustained-release therapies for osteoarthritis. Its lead program, SYN321 (diclofenac linked to hyaluronan), aims to address the significant unmet need in OA by providing prolonged pain relief and anti-inflammatory action directly in the joint, potentially becoming a preferred second-line treatment. The company initiated a first-in-human trial in August 2025 and is positioned in the large, growing global OA market, backed by a strong IP portfolio valid until 2035+. Key risks include clinical trial outcomes, regulatory hurdles, and competition in the crowded OA space.

Therapeutic Areas

Other Symptomatic Knee Osteoarthritis Drugs